Texture analysis of apparent diffusion coefficient maps: can it identify nonresponse to neoadjuvant chemotherapy for additional radiation therapy in rectal cancer patients?
Open Access
- 22 December 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goae035
Abstract
Neoadjuvant chemotherapy (NCT) alone can achieve comparable treatment outcomes to chemoradiotherapy in locally advanced rectal cancer (LARC) patients. This study aimed to investigate the value of texture analysis (TA) in apparent diffusion coefficient (ADC) maps for identifying non-responders to NCT. This retrospective study included patients with LARC after NCT, and they were categorized into nonresponse group (pTRG 3) and response group (pTRG 0–2) based on pathological tumor regression grade (pTRG). Predictive texture features were extracted from pre- and post-treatment ADC maps to construct a TA model using RandomForest. The ADC model was developed by manually measuring pre- and post-treatment ADC values and calculating their changes. Simultaneously, subjective evaluations based on magnetic resonance imaging assessment of TRG were performed by two experienced radiologists. Model performance was compared using the area under the curve (AUC) and DeLong test. A total of 299 patients from two centers were divided into three cohorts: the primary cohort (center A; n = 194, with 36 non-responders and 158 responders), the internal validation cohort (center A; n = 49, with 9 non-responders) and external validation cohort (center B; n = 56, with 33 non-responders). The TA model was constructed by post_mean, mean_change, post_skewness, post_entropy, and entropy_change, which outperformed both the ADC model and subjective evaluations with an impressive AUC of 0.997 (95% confidence interval [CI], 0.975–1.000) in the primary cohort. Robust performances were observed in internal and external validation cohorts, with AUCs of 0.919 (95% CI, 0.805–0.978) and 0.938 (95% CI, 0.840–0.985), respectively. The TA model has the potential to serve as an imaging biomarker for identifying nonresponse to NCT in LARC patients, providing a valuable reference for these patients considering additional radiation therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82001765)
This publication has 37 references indexed in Scilit:
- Diffusion-weighted magnetic resonance imaging of mucin pools in locally advanced rectal mucinous adenocarcinoma predicts tumor response to neoadjuvant therapyEuropean Journal of Radiology, 2020
- Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapyEuropean Radiology, 2018
- Haralick’s texture features for the prediction of response to therapy in colorectal cancer: a preliminary studyLa radiologia medica, 2017
- Diffusion-weighted MRI and MR- volumetry - in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancerMagnetic Resonance Imaging, 2015
- Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: Preliminary results of a monoinstitutional prospective studyEuropean Journal of Surgical Oncology, 2013
- Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularityJournal of Magnetic Resonance Imaging, 2010
- Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancerClinical Radiology, 2008
- The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Interpretation of Magnetic Resonance Imaging for Locally Advanced Rectal Carcinoma After Preoperative Chemoradiation TherapyDiseases of the Colon & Rectum, 2005
- Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trialsThe Lancet, 2001